NCT05786716 DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Status RECRUITING Phase PHASE2/PHASE3
NCT05770544 DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Status RECRUITING Phase PHASE2/PHASE3
NCT05770102 DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Status RECRUITING Phase PHASE2/PHASE3
NCT05770037 DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Status RECRUITING Phase PHASE2/PHASE3
NCT05768178 DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Status RECRUITING Phase PHASE2/PHASE3
NCT05722886 DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Status RECRUITING Phase PHASE2/PHASE3
NCT05635344 A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia Status RECRUITING Phase PHASE2
NCT05615818 Personalized Medicine for Advanced Biliary Cancer Patients Status RECRUITING Phase PHASE3
NCT05574647 Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer Status RECRUITING Phase NA
NCT05534906 The Detection of Small Early Liver Cancer With Natural History Follow up Status RECRUITING Phase N/A
NCT05097274 The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. Status RECRUITING Phase N/A
NCT05082259 ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab Status RECRUITING Phase PHASE1